Use of Liposomes as an Immunopotentiating Delivery System: in Perspective of Vaccine Development

Owais, Mohammad; Masood, A. K.; Agrewala, Javed N.; Bisht, Deepa; Gupta, C. M.

doi:10.1046/j.1365-3083.2001.00944.x

Cited by 21 publications

(9 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible explanation could be the fact that the APC engagement and help signals provided by the mucosal inoculation route of GC90/IRIV construction are more effective in CD8 þ response promoting than s.c. peptide injection in IFA. In fact, previous studies revealed that antigen encapsulated in liposomes could be successfully delivered simultaneously into the cytosolic as well as endosomal processing pathways of APCs, leading to the generation of both CD4 þ T helper and CD8 þ cytotoxic T cells (Owais et al, 2001). It might be useful to further investigate such aspects in order to highlight and potentiate GC90/IRIV-mediated mechanisms of CTL priming.…”

Section: Gc90/iriv Immunisation In Transgenic Micementioning

confidence: 99%

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

et al. 2003

View full text Add to dashboard Cite

Parathyroid hormone-related protein (PTH-rP), a secreted protein produced by prostate carcinoma and other epithelial cancers, is considered a key agent for the development of bone metastases. We investigated the construct GC90/IRIV, composed of immunopotentiating reconstituted influenza virosomes (IRIV) containing PTH-rP gene plasmids (GC90), as a potential tool for human anticancer immunotherapy into humanised mice transgenic for HLA-A(*)02.01, the human-b2 microglobulin, and the human CD8a molecule. Intranasal administration of GC90/IRIV resulted in the induction of a PTH-rP-specific multiepitope cytotoxic T-cell (CTL) response. Cytotoxic T cells derived from vaccinated mice were capable of lysing in vitro syngenic murine PTH-rP transfectants and human HLA-A(*)02.01 þ /PTH-rP þ prostate carcinoma LNCaP cells as well. The immune response capacity and the absence of any sign of toxicity and/or autoimmunity in vivo suggest the GC90/IRIV vaccine as a valid tool for active specific immunotherapy of human cancers and metastases overexpressing PTH-rP. British Journal of Cancer (2003) (Zaccagnini, 1999) and the development of hormone-resistant metastatic bone metastases is one of the major causes of morbidity and mortality related to this malignancy. Parathyroid hormone-related protein (PTH-rP) is an attractive candidate as a target antigen in the protocol of active specific immunotherapy of prostate carcinoma and epithelial malignancy bone metastases. It was originally described as the factor responsible for humoral hypercalcaemia of malignancy (HHM) (Suva et al, 1987;Francini et al, 1993). It is expressed in 90% of prostate and (spindle-cell) lung cell carcinomas and 95% of bone metastases of epithelial cancers, and is produced in small amounts in normal adult tissues (Iguchi et al,

show abstract

Section: Gc90/iriv Immunisation In Transgenic Micementioning

confidence: 99%

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

et al. 2003

View full text Add to dashboard Cite

show abstract

“…). However, liposomes are known to assist the immunogenic potential of antigens . Hence, we encapsulated Acr1 in the fusogenic liposomes prepared from yeast lipids.…”

Section: Discussionmentioning

confidence: 99%

“…The antigens delivered to antigen‐presenting cells (APCs) normally undergo an exogenous pathway for processing and presentation to CD4 T cells, but not to CD8 T cells. However, fusogenic liposomes prepared from the yeast lipids can deliver antigen into the cytosol of APCs, leading to the generation of not only antigen‐specific CD4 but also CD8 T cells . In addition, liposomes are not only effective adjuvants or vehicles to deliver antigens, but can successfully evoke CD4 T helper type 1 (Th1) and Th2 immunity and enhance memory T cell responses .…”

Section: Introductionmentioning

confidence: 99%

Prime-boost vaccination strategy with bacillus Calmette–Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency

Siddiqui

Amir

Khan

et al. 2015

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Bacillus Calmette–Guérin (BCG) remains the only available and most widely administered vaccine against Mycobacterium tuberculosis (Mtb), yet it fails to protect vaccinated individuals either from primary infection or reactivation of latent tuberculosis (TB). Despite BCG's variable efficacy against TB, the fact remains that BCG imparts protection in children against the disease, indicating that BCG possesses a wide protective antigenic repertoire. However, its failure to impart protection in adulthood can be linked to its failure to generate long‐lived memory response and elicitation of an inadequate immune response against latency‐associated antigens. Therefore, to improve the protective efficacy of BCG, a novel vaccination strategy is required. Consequently, in the present study, we have exploited the vaccination potential of liposomized α‐crystalline 1 (Acr1L), a latency‐associated antigen to induce enduring protective immunity against Mtb in BCG‐primed animals. It is noteworthy that an increase in the multi‐functional [interferon (IFN)‐γhi/tumour necrosis factor (TNF)‐αhi] CD4 and CD8 T cells were observed in BCG‐primed and Acr1L‐boosted (BCG‐Acr1L) animals, compared to BCG alone. Further, substantial expansion of both central memory (CD44hi/CD62Lhi) and effector memory (CD44hi/CD62Llo) populations of CD4 and CD8 T cells was noted. Importantly, BCG‐Acr1L exhibited significantly better protection than BCG, as evidenced by a reduction in the bacterial burden and histopathological data of the lungs. In essence, BCG‐Acr1L could be a potent future vaccination strategy to reinvigorate BCG potency.

show abstract

“…A large number of particulate carriers are now available for antigen delivery to APCs and uptake of particulate carriers with or without surface-conjugated targeting ligands by APCs has been demonstrated in in vitro and in vivo animal studies [4, 72, 73]. The recent emergence of carriers to deliver antigens and drugs to cells by carbohydrate ligands for lectin receptors has also demonstrated the exciting potential for developing new therapeutic technology [74, 75].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status

Kojima

Ishii

Kawauchi

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant implications for vaccine design. In this paper, we summarize the potential for liposomes coated with the neoglycolipids containing oligomannose residues (OMLs) as a novel adjuvant for induction of Th1 immune responses and CTLs specific for the encased antigen. OMLs preferentially take up peripheral phagocytic cells. In response to OML uptake, the cells secrete IL-12 selectively, enhance the expression of costimulatory molecules, and migrate into lymphoid tissues from peripheral tissues. OMLs also have the ability to deliver encapsulated protein antigens to the MHC class I and class II pathways to generate antigen-specific CTLs and Th1 cells, respectively, and lipid antigen to CD1d to activate NKT cells. Since administration of OML-based vaccines can eliminate an established tumor, inhibit elevation of the serum IgE level, and prevent progression of protozoan infections in several murine, human, and bovine models, OML-based vaccines have revealed their potential for clinical use in vaccination for a variety of diseases in which CTLs and/or Th1 cells act as effector cells.

show abstract

Use of Liposomes as an Immunopotentiating Delivery System: in Perspective of Vaccine Development

Cited by 21 publications

References 21 publications

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

Prime-boost vaccination strategy with bacillus Calmette–Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency

Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status

Contact Info

Product

Resources

About